India As managing director of India’s fifth largest pharmaceutical company, Zydus Cadila’s Sharvil Patel shares his insights on his impressive internationalization strategy with a special focus on the US where Zydus recently received permission to conduct Phase II clinical studies of Lipaglyn, the first drug to treat patients with nonalcoholic steatohepatitis…
India Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in the next few years and an increasing global focus on improving healthcare access and the cost of care. Against this…
Mexico M.S. Nagendra, Director General at Zydus Pharmaceuticals Mexico, explains the company’s unique business model, combining both branded generics and highly innovative medicines, while showcasing the strategic relevance of the Mexican affiliate within the global strategy of the company. Could you introduce yourself to our international readers as well as the…
Zydus Group You have very successfully executed a vision that you have had for the company since it was a 200 Rs Cr turnover, India-focused enterprise 15 years ago. You have had 18-fold growth since then, and you are set to achieve 1Bn USD in turnover for the first time this March!…
See our Cookie Privacy Policy Here
